Treatment of choroidal neovascularization in high myopia.
High myopia affects approximately 2% of general population, and is a major cause of legal blindness in many developed countries. Choroidal neovascularization (CNV) is the most common vision-threatening complication of high myopia. Different therapeutic approaches have been attempted such as thermal laser photocoagulation, surgery and photodynamic therapy with verteporfin (PDT). The visual outcome of these therapies has been reported to be better than the natural history of the condition. However, the limited visual acuity improvement after PDT monotherapy and the appearance of subretinal fibrosis and chorioretinal atrophy prompted the association of other therapies. In the past few years a tremendous advance in the knowledge of the mechanisms underling CNV secondary to high myopia and age related macular degeneration has been achieved, leading to new therapeutic targets and novel drugs and combined therapies. These new therapeutic weapons have been designed to achieve a selective shut down of choroidal new vessels. Recent reviews have been published on the natural history and therapies for myopic CNV. Ohno-Matsui reported on the natural history of the condition as well as the outcome of laser photocoagulation, surgical extraction of CNV, foveal translocation and photodynamic therapy on myopic CNV in the short-term. Soubrane et al reviewed the new advances on surgery, laser photocoagulation and PDT, considering some of the potential effects of triamcinolone, pegaptanib and ranibizumab in CNV secondary to age related macular degeneration (AMD). Novack et al reported on the pharmacological therapy of CNV in AMD. The aim of this review is to summarize the recent advances in myopic CNV pathophysiology and the new therapeutic targets and drugs that are changing the clinical management of myopic CNV.
Montero
Javier A
JA
Pío del Río Hortega University Hospital, Ophthalmology Unit. C/ Carraca s/n, Valladolid 47012, Spain. javmonmor@hotmail.com
Ruiz-Moreno
Jose M
JM
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology* / Q000503:physiopathology; D018450:Disease Progression; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D056965:Injections, Intraocular; D047728:Myopia, Degenerative / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use; D000077362:Verteporfin
D020533:Angiogenesis Inhibitors; D015507:Drugs, Investigational; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin